Gynecologic Cancers Statistics in the I.R. Iran in 2020
Abstract
Background: Gynecologic cancers (GCs) are among the leading causes of morbidity and mortality in females worldwide. Estimating the cancer burden is invaluable to set up priorities for research funding allocations, cancer control policies, and prevention strategies. The International Agency for Research on Cancer (IARC) has recently released the latest estimates on the prevalence, incidence, and mortality for 36 types of cancer and all cancer sites combined in 185 countries in 2020. Methods: We obtained data on the incidence, mortality, and prevalence of GCs in the Iranian female population from the GLOBOCAN 2020 database presented by the IARC, compared the burden with the previous reports presented in 2012 and 2018, and provided the estimates for 2040. In addition, we compared the burden to that of the WHO Eastern Mediterranean Region (EMRO) and the world. Results: There has been a slight increase in the incidence of GCs in recent years after stable rates for a couple of decades. The growing availability of incidence rates from population-based cancer registries (PBCRs) and mortality rates from vital statistics offices in Iran may account for the increasing trend. Conclusions: Cancer awareness campaigns and high-quality prevention programs may result in better GC prevention among women.
1. Against My Will. Defying the Practices That Harm Women and Girls and Undermine Equality. State of World Population 2020. UNFPA 164 p. www.unfpa.org/sites/default/files/pub-pdf/UNFPA_PUB_2020_EN_State_of_ World_Population.pdf.
2. Peters SA, Woodward M, Jha V, Kennedy S, Norton R. Women's health: a new global agenda. BMJ global health. 2016;1(3):e000080.
3. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best practice & research Clinical obstetrics & gynaecology. 2006;20(2):207-25.
4. National Cancer Institute, Publications, Dictionaries, Cancer Terms, Gynecologic Cancer [Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/gynecologic-cancer.
5. Ledford LR, Lockwood S, editors. Scope and epidemiology of gynecologic cancers: an overview. Seminars in oncology nursing; 2019: Elsevier.
6. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA network open. 2021;4(4):e214708.
7. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [14 12 2020].
8. Latest Global Cancer Data [Available from: https://www.iarc.who.int/faq/latest-global-cancer-data-2020-qa/.
9. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
10. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
11. Cancer Today, Population fact sheets, Global Cancer Observatory.
12. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, B HR, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecologic oncology. 2013;128(2):277-81.
13. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
14. Maliheh A, Noghabaei G. Comparison of age-standard incidence rate trends of gynecologic and breast cancer in Iran and other countries. Iranian journal of public health. 2014;43(10):1372.
15. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a Cancer Journal for Clinicians. 2021;71(1):7-33.
16. Mohebbi E, Nahvijou A, Hadji M, Rashidian H, Seyyedsalehi MS, Nemati S, et al. Iran Cancer Statistics in 2012 and projection of cancer incidence by 2035. Basic & Clinical Cancer Research. 2017;9(3):3-22.
17. Salavatiha Z, Farahmand M, Shoja Z, Jalilvand S. A meta‐analysis of human papillomavirus prevalence and types among Iranian women with normal cervical cytology, premalignant lesions, and cervical cancer. Journal of Medical Virology. 2021.
18. Nahvijou A, Daroudi R, Tahmasebi M, Amouzegar Hashemi F, Rezaei Hemami M, Akbari Sari A, et al. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PloS one. 2016;11(6):e0156705.
19. Majidi A, Ghiasvand R, Hadji M, Nahvijou A, Mousavi A-S, Pakgohar M, et al. Priority setting for improvement of cervical cancer prevention in Iran. International journal of health policy and management. 2016;5(4):225.
20. Khatibi M, Rasekh HR, Shahverdi Z. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iranian journal of pharmaceutical research: IJPR. 2014;13(Suppl):225.
21. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-96.
22. Nahvijou A, Mohagheghi MA, Guiti M, Mahouri A, Tabari NF, Raesspour F, et al. The Role of Cancer Charities in Breast Cancer Prevention in Iran. Basic & Clinical Cancer Research. 2020;12(4).
2. Peters SA, Woodward M, Jha V, Kennedy S, Norton R. Women's health: a new global agenda. BMJ global health. 2016;1(3):e000080.
3. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best practice & research Clinical obstetrics & gynaecology. 2006;20(2):207-25.
4. National Cancer Institute, Publications, Dictionaries, Cancer Terms, Gynecologic Cancer [Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/gynecologic-cancer.
5. Ledford LR, Lockwood S, editors. Scope and epidemiology of gynecologic cancers: an overview. Seminars in oncology nursing; 2019: Elsevier.
6. Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated Projection of US Cancer Incidence and Death to 2040. JAMA network open. 2021;4(4):e214708.
7. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/today, accessed [14 12 2020].
8. Latest Global Cancer Data [Available from: https://www.iarc.who.int/faq/latest-global-cancer-data-2020-qa/.
9. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
10. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424.
11. Cancer Today, Population fact sheets, Global Cancer Observatory.
12. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, B HR, et al. Epidemiology of cervical cancer and human papilloma virus infection among Iranian women - analyses of national data and systematic review of the literature. Gynecologic oncology. 2013;128(2):277-81.
13. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
14. Maliheh A, Noghabaei G. Comparison of age-standard incidence rate trends of gynecologic and breast cancer in Iran and other countries. Iranian journal of public health. 2014;43(10):1372.
15. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a Cancer Journal for Clinicians. 2021;71(1):7-33.
16. Mohebbi E, Nahvijou A, Hadji M, Rashidian H, Seyyedsalehi MS, Nemati S, et al. Iran Cancer Statistics in 2012 and projection of cancer incidence by 2035. Basic & Clinical Cancer Research. 2017;9(3):3-22.
17. Salavatiha Z, Farahmand M, Shoja Z, Jalilvand S. A meta‐analysis of human papillomavirus prevalence and types among Iranian women with normal cervical cytology, premalignant lesions, and cervical cancer. Journal of Medical Virology. 2021.
18. Nahvijou A, Daroudi R, Tahmasebi M, Amouzegar Hashemi F, Rezaei Hemami M, Akbari Sari A, et al. Cost-effectiveness of different cervical screening strategies in Islamic Republic of Iran: a middle-income country with a low incidence rate of cervical cancer. PloS one. 2016;11(6):e0156705.
19. Majidi A, Ghiasvand R, Hadji M, Nahvijou A, Mousavi A-S, Pakgohar M, et al. Priority setting for improvement of cervical cancer prevention in Iran. International journal of health policy and management. 2016;5(4):225.
20. Khatibi M, Rasekh HR, Shahverdi Z. Cost-effectiveness evaluation of quadrivalent human papilloma virus vaccine for HPV-related disease in Iran. Iranian journal of pharmaceutical research: IJPR. 2014;13(Suppl):225.
21. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(4):284-96.
22. Nahvijou A, Mohagheghi MA, Guiti M, Mahouri A, Tabari NF, Raesspour F, et al. The Role of Cancer Charities in Breast Cancer Prevention in Iran. Basic & Clinical Cancer Research. 2020;12(4).
| Files | ||
| Issue | Vol 13 No 2 (2021) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/bccr.v13i2.10026 | |
| Keywords | ||
| Gynecologic Cancers Uterine Cancer Ovarian Cancer Cervical Cancer Cancer Burden | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Rostami S, Nahvijou A. Gynecologic Cancers Statistics in the I.R. Iran in 2020. Basic Clin Cancer Res. 2022;13(2):111-118.
